Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company specializing in oral recombinant pill vaccines, has announced its participation in the upcoming H.C. Wainwright Global Investment Conference.
Management will deliver their presentation on Monday, September 8, 2025, at 12:00 PM ET. The presentation will be accessible via webcast on the company's investor relations website, with a replay available for 30 days after the event. Investors can arrange meetings with management through their H.C. Wainwright representatives.
Vaxart (OTCQX: VXRT), azienda biotecnologica in fase clinica specializzata in vaccini ricombinanti orali in formato pillola, ha annunciato la partecipazione al prossimo H.C. Wainwright Global Investment Conference.
La direzione terr脿 la presentazione luned矛 8 settembre 2025 alle 12:00 ET. La presentazione sar脿 trasmessa in webcast sul sito degli investitori della societ脿 e sar脿 disponibile in replica per 30 giorni dopo l'evento. Gli investitori possono organizzare incontri con la direzione attraverso i loro rappresentanti H.C. Wainwright.
Vaxart (OTCQX: VXRT), una compa帽铆a biotecnol贸gica en fase cl铆nica especializada en vacunas orales recombinantes en formato p铆ldora, ha anunciado su participaci贸n en la pr贸xima H.C. Wainwright Global Investment Conference.
La direcci贸n ofrecer谩 su presentaci贸n el lunes 8 de septiembre de 2025 a las 12:00 PM ET. La presentaci贸n estar谩 disponible por webcast en la web de relaciones con inversores de la compa帽铆a y habr谩 una retransmisi贸n accesible durante 30 d铆as tras el evento. Los inversores pueden concertar reuniones con la direcci贸n a trav茅s de sus representantes de H.C. Wainwright.
Vaxart (OTCQX: VXRT)電� 瓴疥惮順� 鞛“頃� 頃� 韺╉劙 氚膘嫚鞚� 鞝勲鞙茧 頃橂姅 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 須岇偓搿�, 雼り皜鞓る姅 H.C. Wainwright Global Investment Conference鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
瓴届榿歆勋潃 2025雲� 9鞗� 8鞚� 鞗旍殧鞚� 鞓ろ泟 12:00(霃欕秬鞁滉皠)鞐� 氚滍憸毳� 歆勴枆頃╇媹雼�. 氚滍憸電� 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼搿� 鞁滌箔頃� 靾� 鞛堨溂氅�, 頄夓偓 膦呺 頉� 30鞚缄皠 鞛儩鞚� 鞝滉车頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛愲摛鞚� H.C. Wainwright 雼措嫻鞛愲ゼ 韱淀暣 瓴届榿歆勱臣鞚� 氙疙寘鞚� 鞁犾箔頃� 靾� 鞛堨姷雼堧嫟.
Vaxart (OTCQX: VXRT), une soci茅t茅 biotechnologique en phase clinique sp茅cialis茅e dans les vaccins recombinants oraux sous forme de comprim茅, a annonc茅 sa participation 脿 la prochaine H.C. Wainwright Global Investment Conference.
La direction pr茅sentera le lundi 8 septembre 2025 脿 12h00 ET. La pr茅sentation sera accessible en webcast sur le site relations investisseurs de la soci茅t茅, avec une rediffusion disponible pendant 30 jours apr猫s l'茅v茅nement. Les investisseurs peuvent organiser des r茅unions avec la direction via leurs repr茅sentants H.C. Wainwright.
Vaxart (OTCQX: VXRT), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf orale rekombinante Tablettenimpfstoffe spezialisiert hat, hat seine Teilnahme an der kommenden H.C. Wainwright Global Investment Conference angek眉ndigt.
Das Management wird seine Pr盲sentation am Montag, den 8. September 2025, um 12:00 Uhr ET halten. Die Pr盲sentation wird per Webcast auf der Investor-Relations-Website des Unternehmens zug盲nglich sein; eine Wiederholung steht 30 Tage nach der Veranstaltung zur Verf眉gung. Investoren k枚nnen 眉ber ihre H.C. Wainwright-Ansprechpartner Meetings mit dem Management vereinbaren.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- SOUTH SAN FRANCISCO, Calif., September 2, 2025 鈥� Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that management will present at the H.C. Wainwright Global Investment Conference taking place September 8-10, 2025.
Presentation Details:
Date and Time:听Monday, September 8 at听12:00 PM ET
奥别产肠补蝉迟:听
A live webcast will be available on the Company鈥檚 investor relations website at , and a replay of the presentation will be available for 30 days following the conclusion of the event.
Investors interested in meeting with management during the conference may reach out to their H.C. Wainwright representative.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart鈥檚 development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart鈥檚 first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
| Vaxart听Media and Investor Relations: |
| Matt Steinberg |
| FINN Partners |
| [email protected] |
| (646) 871-8481 |
| 听 |
This press release was published by a CLEAR庐 Verified individual.
FAQ
When is Vaxart (VXRT) presenting at the H.C. Wainwright Conference 2025?
How can investors access Vaxart's (VXRT) H.C. Wainwright presentation?
What does Vaxart (VXRT) specialize in?
How can investors meet with Vaxart management during the conference?
